Treatment for Adult Peritonsillar Cellulitis
For adults with peritonsillar cellulitis, empirical antibiotic therapy targeting β-hemolytic streptococci is the primary treatment, with oral penicillin or amoxicillin as first-line agents, combined with supportive care including hydration and pain control.
Initial Assessment and Diagnosis
Peritonsillar cellulitis represents inflammation of the peritonsillar space without frank abscess formation. Key clinical features to identify include:
- Unilateral tonsillar enlargement with peritonsillar edema
- Dysphagia and odynophagia (difficulty and painful swallowing)
- Fever and systemic symptoms
- Trismus (jaw stiffness) - though less predictive of cellulitis vs abscess 1
- "Hot potato" voice (muffled speech)
- Uvular deviation may or may not be present
Critical distinction: If needle aspiration yields pus, this is a peritonsillar abscess requiring drainage, not cellulitis. Cellulitis by definition has no drainable collection 2, 1.
Antibiotic Selection
First-Line Therapy (Outpatient)
β-lactam antibiotics are recommended as first-line treatment since the primary pathogens are Group A β-hemolytic streptococci, with Group C/G streptococci and Streptococcus pneumoniae also implicated 1:
- Penicillin V 500 mg PO four times daily, OR
- Amoxicillin 500 mg PO three times daily
Duration: At least 10 days of total antibiotic therapy is recommended to minimize recurrence risk 3.
Alternative Regimens
If MRSA coverage is needed (nonpurulent cellulitis not responding to β-lactam therapy or systemic toxicity present):
Clindamycin 300-450 mg PO three times daily 4
- Provides coverage for both streptococci and MRSA
- However, recent evidence shows no superiority over penicillin for peritonsillar infections 5
- Consider collateral damage to gut microbiota and C. difficile risk
Combination therapy: TMP-SMX or doxycycline PLUS amoxicillin if dual coverage desired 4
Inpatient Therapy
For patients requiring hospitalization (severe systemic toxicity, inability to tolerate oral intake, immunocompromised):
- Ampicillin-sulbactam 3 g IV every 6 hours, OR
- Penicillin G IV with metronidazole for anaerobic coverage
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours if MRSA suspected 4
Early oral switch therapy is appropriate once the patient can tolerate oral intake and shows clinical improvement, typically after 2-3 days 3, 2.
Supportive Care
- Hydration: IV fluids if unable to maintain oral intake
- Pain control: NSAIDs or acetaminophen; opioids if severe
- Corticosteroids: Single dose of dexamethasone may reduce symptoms and speed recovery 2, 6
Monitoring and Follow-Up
Clinical response should be evident within 48-72 hours 2:
- Improvement in dysphagia and trismus
- Defervescence
- Reduction in peritonsillar swelling
If no improvement after 48 hours on β-lactam therapy: Consider MRSA coverage or re-evaluate for abscess formation requiring drainage 4.
Duration and Recurrence Prevention
Total antibiotic duration: Minimum 10 days, preferably 10-14 days 3
- Studies show 10-14 days associated with lower rehospitalization rates (OR 0.86) compared to shorter courses
- Duration ≥15 days shows even lower recurrence (OR 0.51) 3
Common Pitfalls to Avoid
Failing to distinguish cellulitis from abscess: Always attempt needle aspiration if clinical suspicion for abscess exists. Cellulitis alone does not require surgical drainage 2, 1.
Inadequate antibiotic duration: Courses shorter than 10 days increase recurrence risk significantly 3.
Unnecessary MRSA coverage: For typical peritonsillar cellulitis, β-hemolytic streptococci are the primary pathogens. Reserve MRSA coverage for treatment failures or specific risk factors 4.
Overuse of clindamycin: While effective, clindamycin offers no advantage over penicillin for peritonsillar infections and carries greater adverse effect burden 5.
Hospitalization Criteria
Admit patients with:
- Severe systemic toxicity or sepsis
- Inability to maintain oral hydration
- Airway compromise concerns
- Immunocompromised status
- Failed outpatient management 7, 6
Most patients with uncomplicated peritonsillar cellulitis can be managed as outpatients with close follow-up 6.